Researchers at the Institute of Science Tokyo have developed a blood-based test that measures cholesterol efflux capacity (CEC), a key indicator of how well high-density lipoprotein (HDL) removes cholesterol from artery walls. Published in the journal Atherosclerosis, the study suggests that low CEC levels correlate with the presence of high-risk, lipid-rich coronary plaques, offering a potential new tool for identifying patients at risk of acute cardiovascular events.
How does the new cholesterol efflux capacity test work?
The new method, termed immobilized liposome-bound gel beads (ILG), simplifies the assessment of HDL function by measuring its ability to extract excess cholesterol from cells. Led by Professor Ryunosuke Ohkawa and Professor Emeritus Minoru Tozuka, the research team designed the ILG process to bypass the technical complexities of older, traditional testing methods. According to the study, this approach provides a more practical, reliable way to quantify how effectively an individual’s HDL transports cholesterol to the liver for metabolism.
Why is HDL function more predictive than standard cholesterol levels?
Standard blood tests typically measure cholesterol concentration, but these figures often fail to reflect the dynamic nature of HDL particles. In the Institute of Science Tokyo study, researchers analyzed 61 patients who had undergone cardiac catheterization. They compared the patients’ CEC values against images obtained through optical coherence tomography. The data showed that patients with large, unstable lipid-rich plaques had significantly lower CEC values. This suggests that the biological activity of HDL—specifically its role in preventing plaque accumulation—is a more accurate predictor of cardiovascular vulnerability than simple concentration metrics.
What role does apolipoprotein E play in heart health?
The research team identified a link between higher CEC values and HDL particles that contain apolipoprotein E (apoE). These specific particles appear to be more efficient at removing cholesterol from cells. By identifying patients who lack this functionality, clinicians may be able to better pinpoint those at risk of plaque rupture, which is a primary trigger for acute coronary syndromes. This biomarker could shift the focus of preventive cardiology from managing total cholesterol levels to optimizing the underlying function of protective lipoproteins.
How will this change cardiovascular clinical care?
Currently, detecting vulnerable plaques often requires invasive procedures like cardiac catheterization. The ILG method aims to provide a non-invasive, blood-based alternative for risk stratification. According to Professor Ohkawa, the primary goal of the research is to make CEC measurement accessible for routine clinical practice. If validated in larger, multi-center trials, this test could allow physicians to monitor patients more precisely after a cardiovascular event and adjust preventive strategies before a plaque rupture occurs.
Frequently Asked Questions
What is cholesterol efflux capacity (CEC)?
CEC is a measurement of the biological ability of HDL particles to remove excess cholesterol from cells and transport it to the liver for removal from the body.
How is the ILG method different from standard tests?
Standard tests measure the volume of cholesterol in the blood. The ILG method uses immobilized liposome-bound gel beads to measure the actual performance and function of HDL particles.
Can this test predict a heart attack?
The researchers note that lower CEC values are associated with high-risk, lipid-rich plaques. While not a standalone predictor, it serves as a biomarker to help physicians identify patients who may be at a higher risk of acute coronary syndromes.
Are you interested in the latest developments in cardiovascular health? Subscribe to our newsletter for updates on diagnostic breakthroughs and heart-healthy research.
